(Q36365463)

13 August 2017

1 reference

title

Cutaneous melanoma: available therapy for metastatic disease (English)

1 reference

13 August 2017

Ahmad A Tarhini

1

1 reference

13 August 2017

Sanjiv S Agarwala

series ordinal

2

1 reference

13 August 2017

publication date

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

19

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

19-25

1 reference

Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Heat shock protein-peptide complexes in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00052.X

Systemic treatments for metastatic cutaneous melanoma.

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001215

Identifiers

DOI

10.1111/J.1529-8019.2005.00052.X

1 reference

13 August 2017

1 reference